Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for left bundle branch block in heart failure.
Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion ...
BACKGROUND: Premature atrial contractions (PACs) are independently associated with atrial fibrillation, stroke, and heart ...
Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
A growing body of research seeks to validate ctDNA as a means of guiding MIBC treatment, particularly immunotherapy.
Morning Overview on MSN
Psilocybin study links EEG signature to reported mystical experiences
A double-blind, randomized trial has identified specific brainwave patterns that track with the mystical and ...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...
And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results